Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Rating of “Hold” by Analysts

Shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) have been given a consensus recommendation of “Hold” by the thirteen ratings firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $45.43.

DCPH has been the topic of several research analyst reports. ValuEngine upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 1st. Canaccord Genuity decreased their price objective on shares of Deciphera Pharmaceuticals from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, March 15th. Zacks Investment Research cut shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Finally, BidaskClub upgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 2nd.

In other Deciphera Pharmaceuticals news, insider Michael Douglas Taylor sold 9,431 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $28.85, for a total transaction of $272,084.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas Patrick Kelly sold 1,500 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $30.00, for a total transaction of $45,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,314 shares of company stock worth $1,156,119. 20.61% of the stock is owned by company insiders.



A number of hedge funds and other institutional investors have recently modified their holdings of DCPH. Millennium Management LLC grew its position in Deciphera Pharmaceuticals by 1,405.1% during the fourth quarter. Millennium Management LLC now owns 1,246,640 shares of the company’s stock valued at $26,167,000 after acquiring an additional 1,163,815 shares during the last quarter. BlackRock Inc. grew its position in Deciphera Pharmaceuticals by 73.6% during the fourth quarter. BlackRock Inc. now owns 1,173,245 shares of the company’s stock valued at $24,625,000 after acquiring an additional 497,427 shares during the last quarter. Orbimed Advisors LLC grew its position in Deciphera Pharmaceuticals by 25.0% during the fourth quarter. Orbimed Advisors LLC now owns 2,442,200 shares of the company’s stock valued at $51,262,000 after acquiring an additional 488,700 shares during the last quarter. Norges Bank bought a new position in Deciphera Pharmaceuticals during the fourth quarter valued at approximately $6,974,000. Finally, Sofinnova Investments Inc. bought a new position in Deciphera Pharmaceuticals during the fourth quarter valued at approximately $5,572,000. Institutional investors and hedge funds own 56.15% of the company’s stock.

Shares of Deciphera Pharmaceuticals stock traded up $0.21 on Friday, reaching $23.33. The stock had a trading volume of 2,171 shares, compared to its average volume of 159,444. Deciphera Pharmaceuticals has a 1 year low of $18.55 and a 1 year high of $45.61. The company has a market cap of $880.66 million, a price-to-earnings ratio of -8.27 and a beta of 3.04. The company has a current ratio of 9.55, a quick ratio of 13.24 and a debt-to-equity ratio of 0.01.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.41). On average, sell-side analysts predict that Deciphera Pharmaceuticals will post -3.23 earnings per share for the current year.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

See Also: Market Capitalization and Individual Investors

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.